Jasmonates: Novel anticancer agents acting directly and selectively on human cancer cell mitochondria

Cancer Research

Volumn 65, Issue 5, 2005, Pages 1984-1993

  Rotem, Ronit ^a   Heyfets, Alina ^a   Fingrut, Orit ^a   Blickstein, Dorit ^b   Shaklai, Mati ^b   Flescher, Eliezer ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b RABIN MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

JASMONIC ACID;

ARTICLE; CANCER CELL; CELL SWELLING; CHEMICAL ANALYSIS; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LEUKEMIA CELL; MEMBRANE DEPOLARIZATION; MITOCHONDRIAL MEMBRANE; MITOCHONDRION; PRIORITY JOURNAL; SPECTROPHOTOMETRY; WESTERN BLOTTING;

ACETIC ACIDS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CALCIUM; CARCINOMA, HEPATOCELLULAR; CELL MEMBRANE PERMEABILITY; CELLS, CULTURED; CYCLOPENTANES; CYTOCHROMES C; FIBROBLASTS; FLOW CYTOMETRY; HUMANS; ION CHANNELS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; LIVER NEOPLASMS; LYMPHOCYTES; MEMBRANE POTENTIALS; MICE; MITOCHONDRIA; MITOCHONDRIAL MEMBRANE TRANSPORT PROTEINS; MITOCHONDRIAL SWELLING; PLANT GROWTH REGULATORS;

EID: 16444376422     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-3091     Document Type: Article

References (62)

1. Sembdner G, Parthier B. The biochemistry and the physiological and molecular actions of jasmonates. Annu Rev Plant Physiol Plant Mol Biol 1993;44:569-89.
2. Farmer EE, Ryan CA. Interplant communication: airborne methyl jasmonate induces synthesis of proteinase inhibitors in plant leaves. Proc Natl Acad Sci U S A 1990;87:7713-6.
3. Mitler H, Lam E. Sacrifice in the face of foes: pathogen-induced programmed cell death in higher plants. Trends Microbiol 1996;4:10-5.
4. Fingrut O, Flescher E. Plant stress hormones suppress the proliferation and induce apoptosis in human cancer cells. Leukemia 2002;16:608-16.
5. Rotem R, Fingrut O, Moskovitz J, Flescher E. The anticancer agent methyl jasmonate induces activation of stress-regulated c-Jun N-terminal kinase and p38 protein kinase in human lymphoid cells. Leukemia 2003;17:2230-4.
6. Debatin K-M, Poncet D, Kroemer G. Chemotherapy: targeting the mitochondrial cell death pathway. Oncogene 2002;21:8786-803.
7. Newmeyer DD, Ferguson-Miller S. Mitochondria: releasing power for life and unleashing the machineries of death. Cell 2003;112:481-90.
8. Lemasters JJ, Nieminen A-L, Qian T, et al. The mitochondrial permeability transition in cell death: a common mechanism in necrosis, apoptosis and autophagy. Biochim Biophys Acta 1998;1366:177-96.
9. Constantini P, Jacotot E, Decaudin D, Kroemer G. Mitochondrion as a novel target of anticancer chemotherapy. J Natl Cancer Inst 2000;92:1042-53.
10. Marchetti P, Mortier L, Beauvillain V, Formstecher P. Are mitochondria targets of anticancer drugs responsible for apoptosis? Ann Biol Clin (Paris) 2002;60:391-403.
11. Kroemer G. The mitochondrial permeability transition pore complex as a pharmacological target. An introduction. Curr Med Chem 2003;10:1469-72.
12. Zhu X-H, Shen Y-L, Jing Y-K, et al. Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. J Natl Cancer Inst 1999;91:772-8.
13. Kroemer G, de The H. Arsenic trioxide, a novel mitochondriotoxic anticancer agent? J Natl Cancer Inst 1999;91:743-5.
14. Shen ZY, Shen J, Cai WJ, Hong C, Zheng MH. The alteration of mitochondria is an early event of arsenic trioxide induced apoptosis in esophageal carcinoma cells. Int J Mol Med 2000;5:155-8.
15. Tallman MS, Nabhan C, Feusner JH, Rowe JM. Acute promyelocytic leukemia: evolving therapeutic strategies. Blood 2002;99:759-67.
16. Saito M, Korsmeyer SJ, Schlesinger PH. BAX-independent transport of cytochrome c reconstituted in pure liposomes. Nat Cell Biol 2000;2:553-5.
17. Martinou JC, Green DR. Breaking the mitochondrial barrier. Nat Rev Mol Cell Biol 2001;2:63-7.
18. 2+-independent mechanisms that are regulated by Bax. J Biol Chem 2001;276:19066-71.
19. Kuwana T, Mackey MR, Perkins G, et al. Bid, Bax, and lipids cooperate to form supramolecular openings in the outer mitochondrial membrane. Cell 2002;111:331-42.
20. Epand RF, Martinou JC, Montessuit S, Epand RM, Yip CM. Direct evidence for membrane pore formation by the apoptotic protein Bax. Biochem Biophys Res Commun 2002;298:744-9.
21. Sharpe JC, Arnoult D, Youle RJ. Control of mitochondrial permeability by Bcl-2 family members. Biochim Biophys Acta 2004;1644:107-13.
22. Terrones O, Antonsson B, Yamaguchi H, et al. Lipidic pore formation by the concerted action of proapoptotic BAX and tBID. J Biol Chem 2004;279:30081-91.
23. Belzacq A-S, El Hamel C, Vieira HLA, et al. Adenine nucleotide translocator mediates the mitochondrial membrane permeabilization induced by lonidamine, arsenite and CD437. Oncogene 2001;20:7579-87.
24. Marchetti P, Zamzami N, Joseph B, et al. The novel retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid can trigger apoptosis through a mitochondrial pathway independent of the nucleus. Cancer Res 1999;59:6257-66.
25. Jacotot E, Ravagnan L, Loeffler M, et al. The HIV-1 viral protein R induces apoptosis via a direct effect on the mitochondrial permeability transition pore. J Exp Med 2000;191:33-46.
26. Jacotot E, Ferri KF, El Hamel C, et al. Control of mitochondrial membrane permeabilization by adenine nucleotide translocator interacting with HIV-1 viral protein R and Bcl-2. J Exp Med 2001;193:509-20.
27. Castedo M, Perfettini J-L, Kroemer G. Mitochondrial apoptosis and the peripheral benzodiazepine receptor: a novel target for viral and pharmacological manipulation. J Exp Med 2002;196:1121-5.
28. Waldmeier PC, Zimmermann K, Qian T, Tintelnot-Blomley M, Lemasters JJ. Cyclophilin D as a drug target. Curr Med Chem 2003;10:1485-506.
29. Shou Y, Li L, Prabhakaran K, Borowitz JL, Isom GE. Calcineurin-mediated BAD translocation regulates cyanide-induced neuronal apoptosis. Biochem J 2004;379:805-13.
30. Marchetti P, Castedo M, Susin SA, et al. Mitochondrial permeability transition is a central coordinating event of apoptosis. J Exp Med 1996;184:1155-60.
31. Huser J and Blatter LA. Fluctuations in mitochondrial membrane potential caused by repetitive gating of the permeability transition pore. Biochem J 1999;343:311-7.
32. Blattner JR, He L, Lemasters JJ. Screening assays for the mitochondrial permeability transition using a fluorescence multiwell plate reader. Anal Biochem 2001;295:220-6.
33. Katzung BG. Nonsteroidal anti-inflammatory drugs, disease-modifying antirheumatic drugs, nonopioid analgesics, & drugs used in gout In: Katzung BG, editor. Basic and clinical pharmacology. Stamford (CT): Appleton & Lange; 1998. p. 578-602.
34. Arora AS, Jones BJ, Patel TC, Bronk SF, Gores GJ. Ceramide induces hepatocyte cell death through disruption of mitochondrial function in the rat. Hepatology 1997;35:958-63.
35. You K-S. Salicylate and mitochondrial injury in Reye's syndrome. Science 1983;221:163-5.
36. Martens ME, Lee C-P. Reye's syndrome: salicylates and mitochondrial functions. Biochem Pharmacol 1984;33:2869-76.
37. Trost LC, Lemasters JJ. The mitochondrial permeability transition: a new pathophysiological mechanism for Reye's syndrome and toxic liver injury. J Pharmacol Exp Ther 1996;278:1000-5.
38. Al-Nasser I. Salicylate-induced kidney mitochondrial permeability transition is prevented by cyclosporine A. Toxicol Lett 1999;105:1-8.
39. Godbole A, Varghese J, Sarin A, Mathew MK. VDAC is a conserved element of death pathways in plant and animal systems. Biochim Biophys Acta 2003;1642:87-96.
40. Chen LB. Mitochondrial membrane potential in living cells. Annu Rev Cell Biol 1988;4:155-81.
41. Dang CV, Semenza GL. Oncogenic alterations of metabolism. Trends Biochem Sci 1999;24:68-72.
42. Cuezva JM, Krajewska M, de Heredia ML, et al. The bioenergetic signature of cancer: a marker of tumor progression. Cancer Res 2002;62:6674-81.
43. Isidoro A, Martinez M, Fernandez PL, et al. Alteration of the bioenergetic phenotype of mitochondria is a hallmark of breast, gastric, lung and oesophageal cancer. Biochem J 2004;378:17-20.
44. Cao TM, Coutre SE. Management of advanced chronic lymphocytic leukemia. Curr Hematol Rep 2003;2:65-72.
45. Morra E, Nosari A, Montillo M. Infectious complications in chronic lymphocytic leukemia. Hematol Cell Ther 1999;41:145-51.
46. Schiavone EM, De Simone M, Palmieri S, et al. Fludarabine plus cyclophosphamide for the treatment of advanced chronic lymphocytic leukemia. Eur J Haematol 2003;71:23-8.
47. Leoni LM, Chao Q, Cottam HB, et al. Induction of an apoptotic program in cell-free extracts by 2-chloro-2′-deoxyadenosine 5′-triphosphate and cytochrome C. Proc Natl Acad Sci U S A 1998;95:9567-71.
48. Genini D, Adachi S, Chao Q, et al. Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria. Blood 2000;96:3537-43.
49. Perez-Galan P, Marzo I, Giraldo P, et al. Role of caspases and apoptosis-inducing factor (AIF) in cladribine-induced apoptosis of B cell chronic lymphocytic leukemia. Leukemia 2002;16:2106-14.
50. Billard C, Izard JC, Roman V, et al. Comparative antiproliferative and apoptotic effects of resveratrol, epsilon-viniferin and vine-shots derived polyphenols (vineatrols) on chronic B lymphocytic leukemia cells and normal human lymphocytes. Leuk Lymphoma 2002;43:1991-2002.
51. Moon EY and Lerner A. PDE4 inhibitors activate a mitochondrial apoptotic pathway in chronic lymphocytic leukemia cells that is regulated by protein phosphatase 2A. Blood 2003;101:4122-30.
52. Dewson G, Snowden RT, Almond JB, Dyer MJ, Cohen GM. Conformational change and mitochondrial translocation of Bax accompany proteasome inhibitor-induced apoptosis of chronic lymphocytic leukemia cells. Oncogene 2003;22:2643-54.
53. Kolb JP, Kern C, Quiney C, Roman V, Billard C. Re-establishment of a normal apoptotic process as a therapeutic approach in B-CLL. Curr Drug Targets Cardiovasc Haematol Disord 2003;3:261-86.
54. Giles FJ, Bekele BN, O'Brien S, et al. A prognostic model for survival in chronic lymphocytic leukemia based on p53 expression. Br J Haematol 2003;121:578-85.
55. Thornton PD, Gruszka-Westwood AM, Hamoudi RA, et al. Characterization of TP53 abnormalities in chronic lymphocytic leukemia. Hematol J 2004;5:47-54.
56. Kitada S, Andersen J, Akar S, et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlation with in vitro and in vivo chemoresponses. Blood 1998;91:3379-89.
57. Johnston JB, Paul JT, Neufeld NJ, et al. Role of myeloid cell factor-1 (Mcl-1) in chronic lymphocytic leukemia. Leuk Lymphoma 2004;45:2017-27.
58. Wall NR, Beck FW, Al-Katib AM, Mohammad RM. Treatment-induced expression of anti-apoptotic proteins in WSU-CLL, a human chronic lymphocytic leukemia cell line. J Drug Target 2001;9:329-39.
59. Nakagawa Y, Yamaguchi S, Hasegawa M, et al. Differential expression of survivin in bone marrow cells from patients with acute lymphocytic leukemia and chronic lymphocytic leukemia. Leuk Res 2004;28:487-94.
60. Byrd JC, Stilgenbauer S, Flinn IW. Chronic lymphocytic leukemia. Hematology (Am Soc Hematol Educ Program) 2004:163-83.
61. Don AS, Hogg PJ. Mitochondria as cancer drug targets. Trends Mol Med 2004;10:372-8.
62. Fantin VR, Leder P. F16, a mitochondriotoxic compound, triggers apoptosis or necrosis depending on the genetic background of the target carcinoma cell. Cancer Res 2004;64:329-36.